Privia Health Group, Inc. (PRVA) SEC Filings & Earnings Calls
EquiReason read 15 Privia Health Group, Inc. SEC filings in the last 12 months. Latest: SC 13D on 2026-09-08 — Activist investor Puma Growth Holdings (Rubicon Founders / Adam Boehler) disclosed a 5.07% passive stake in Privia Health Group, Inc..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 2.9B
- P/E TTM
- 106.7
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
8 Sep 2026SC 13DActivist investor Puma Growth Holdings (Rubicon Founders / Adam Boehler) disclosed a 5.07% passive stake in Privia Health Group, Inc.open
Figures in the filing · each found in the filing text
| Beneficial ownership percent · 2026-09-01 | 5.1% |
6 Aug 202610-QPrivia Health reported strong Q2 2026 results with revenue up 21.4% YoY and Adjusted EBITDA up 29.1% YoY, driven by provider growth and VBC expansion.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $633M | +21% y/y |
| Implemented Providers · Q2-2026 | 5,644 | +10% y/y |
| Attributed Lives · Q2-2026 | 1,647,000 | +19% y/y |
| Practice Collections · Q2-2026 | $970M | +12% y/y |
| Care Margin · Q2-2026 | $132M | +15% y/y |
| Platform Contribution · Q2-2026 | $69M | +20% y/y |
| Platform Contribution Margin · Q2-2026 | 52.2% | |
| Adjusted EBITDA · Q2-2026 | $37M | +29% y/y |
| Adjusted EBITDA Margin · Q2-2026 | 28.3% | |
| Operating cash flow · H1-2026 | $-48M | +201% y/y |
Risks flagged
Payer contract renegotiation risk
“If the counterparties fail to renew their contracts, renew their contracts upon less favorable terms or at lower fee levels or fail to utilize additional products and services obtained from us, or if we fail to renegotiate contracts with our counterparties on favorable terms or at all, our revenue may decline and our future revenue growth may be constrained” · word for word
Negative operating cash flow
“Net cash used in operating activities was $48.4 million for the six months ended June 30, 2026 compared to $16.1 million for the same period in 2025” · word for word
6 Aug 20268-K · 2.02Privia Health reported strong Q2 2026 results: revenue $632.6M (+21.4% YoY), net income $9.0M (+236.7% YoY), adjusted EBITDA $37.4M (+29.1% YoY). Raised full-year 2026 guidance across all key metrics.earningsopen
Figures in the filing · each found in the filing text
| Total revenue · Q2-2026 | $633M | +21% y/y |
| Net income · Q2-2026 | $9M | +233% y/y |
| Adjusted EBITDA · Q2-2026 | $37M | +29% y/y |
| Gross profit · Q2-2026 | $129M | +14% y/y |
| Operating income · Q2-2026 | $12M | +258% y/y |
| Non-GAAP adjusted net income · Q2-2026 | $25M | +19% y/y |
| Net income per share · Q2-2026 | $0.07 | +250% y/y |
| Non-GAAP adjusted net income per share · Q2-2026 | $0.19 | +12% y/y |
| Implemented Providers · Q2-2026 | 5,644 | +10% y/y |
| Value-Based Care Attributed Lives · Q2-2026 | 1,647,000 | +19% y/y |
Guidance
FY26 revenue raised to high end of $2.35-2.45B from $2.35-2.45B (high end); Attributed Lives raised to 1,625,000-1,650,000 from 1,550,000-1,600,000; Care Margin raised to mid to high end of $515-530M; Platform Contribution raised to mid to high end of $260-270M; Adjusted EBITDA raised to mid to high end of $145-155M
Raised full-year 2026 guidance across all key metrics reflecting strong momentum in value-based care and provider network growth
Risks flagged
Regulatory and reimbursement risk in heavily regulated healthcare industry
“Risk factors: heavily regulated industry, potential decreases in reimbursement rates, changes to payment terms”
Dependence on key third-party vendor athenahealth for EMR services
“Risk factors: impact of failures by or service disruptions at key third-party vendors, such as athenahealth”
Cybersecurity and data privacy risks
“Risk factors: impact of actual and potential security threats, cybersecurity incidents or privacy or data breaches”
7 May 202610-QRevenue $604M (+26% y/y); Adjusted EBITDA $37M (+36% y/y); Implemented Providers 5,535 (+14% y/y)open
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $604M | +26% y/y |
| Adjusted EBITDA · Q1-2026 | $37M | +36% y/y |
| Implemented Providers · 2026-03-31 | 5,535 | +14% y/y |
| Attributed Lives · 2026-03-31 | 1,606,000 | +27% y/y |
| Practice Collections · Q1-2026 | $915M | +15% y/y |
| Care Margin · Q1-2026 | $129M | +22% y/y |
| Platform Contribution · Q1-2026 | $67M | +30% y/y |
Risks flagged
Dependence on payer contracts and reimbursement rates
“Our FFS and VBC revenue is dependent upon our contracts and relationships with payers. If the counterparties fail to renew their contracts, renew their contracts upon less favorable terms or at lower fee levels... our revenue may decline.” · word for word
Net income decline despite revenue growth
“Net income attributable to Privia Health Group, Inc. was $3.1 million and $4.2 million, for the three months ended March 31, 2026 and 2025, respectively, a 27.4% decrease.” · word for word
7 May 20268-K · 2.02Total revenue $604M (+26% y/y); Gross profit $126M (+21% y/y); Operating income $7M (+42% y/y); Guidance: FY2026: Revenue $2.35B-$2.45B, Adj. EBITDA $145M-$155M, Attributed Lives 1,600,000-1,625,000earningsopen
Figures in the filing · each found in the filing text
| Total revenue · Q1-2026 | $604M | +26% y/y |
| Gross profit · Q1-2026 | $126M | +21% y/y |
| Operating income · Q1-2026 | $7M | +42% y/y |
| Net income · Q1-2026 | $3M | -27% y/y |
| Non-GAAP adjusted net income · Q1-2026 | $24M | +22% y/y |
| Non-GAAP adjusted net income per share · Q1-2026 | $0.19 | +19% y/y |
| Practice Collections · Q1-2026 | $915M | +15% y/y |
| Care Margin · Q1-2026 | $129M | +22% y/y |
| Platform Contribution · Q1-2026 | $67M | +30% y/y |
| Adjusted EBITDA · Q1-2026 | $37M | +36% y/y |
Guidance
FY2026: Revenue $2.35B-$2.45B, Adj. EBITDA $145M-$155M, Attributed Lives 1,600,000-1,625,000
Reiterated full-year guidance for most metrics; raised attributed lives guidance range.
Risks flagged
GAAP net income declined 27.4% YoY due to higher stock compensation expense.
“Net income $3.1 million, -27.4% versus 1Q'25; included $21.9M in non-cash stock compensation expense.”
2 Apr 2026DEF 14AProxy statement filed for 2026 annual meeting, disclosing executive compensation, board refreshment, and strong 2025 operating performance.open
Figures in the filing · each found in the filing text
| Practice Collections · FY2025 | $3.47B | +17% y/y |
| Attributed Lives · 2025-12-31 | 1,541,000 | +23% y/y |
| Implemented Providers · FY2025 | 591 | +12% y/y |
| Net Income · FY2025 | $23M | +59% y/y |
| Adjusted EBITDA · FY2025 | $126M | +39% y/y |
| Revenue · FY2025 | $2.12B | |
| Care Margin · FY2025 | $462M |
Risks flagged
Cybersecurity risk
“In 2025, we did not identify any cybersecurity threats or incidents, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition.” · word for word
Key person / CEO transition risk
“The successful CEO and General Counsel succession processes in 2023 and 2024, respectively, reflect the execution of thoughtful, well-coordinated CEO and executive officer succession plan overseen by the Board.” · word for word
27 Feb 202610-KRevenue $2.12B (+22% y/y); Net Income $23M (+59% y/y); Adjusted EBITDA $126M (+39% y/y)open
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $2.12B | +22% y/y |
| Net Income · FY2025 | $23M | +59% y/y |
| Adjusted EBITDA · FY2025 | $126M | +39% y/y |
| Care Margin · FY2025 | $462M | +14% y/y |
| Platform Contribution · FY2025 | $235M | +20% y/y |
| Implemented Providers · FY2025 | 5,380 | +12% y/y |
| Attributed Lives · FY2025 | 1,541,000 | +23% y/y |
| Practice Collections · FY2025 | $3.47B | +17% y/y |
| Platform Contribution Margin · FY2025 | 50.8% | |
| Adjusted EBITDA Margin · FY2025 | 27.2% |
Risks flagged
History of net losses
“We have a history of net losses, we anticipate increasing expenses in the future, and we may not be able to maintain profitability.” · word for word
Physician recruitment and retention
“The operations and growth strategy of the Company and its Medical Groups depend on our ability to recruit and retain qualified talent, including physicians and non-physician practitioners.” · word for word
Data privacy and security
“Numerous other federal and state laws and regulations protect the confidentiality, privacy, availability, integrity and security of PHI and other types of personal information.” · word for word
26 Feb 20268-K · 2.02Total revenue $2.12B (+22% y/y); Gross profit $453M (+14% y/y); Operating income $34M (+102% y/y); Guidance: FY2026 Adj EBITDA guidance $145M-$155M (midpoint $150M, +20% YoY); revenue $2.35B-$2.45B (midpoint $2.4B, +13% YoY)earningsopen
Figures in the filing · each found in the filing text
| Total revenue · FY2025 | $2.12B | +22% y/y |
| Gross profit · FY2025 | $453M | +14% y/y |
| Operating income · FY2025 | $34M | +102% y/y |
| Net income · FY2025 | $23M | +59% y/y |
| Adjusted EBITDA · FY2025 | $126M | +39% y/y |
| Implemented Providers · FY2025 | 5,380 | +12% y/y |
| Attributed Lives · FY2025 | 1,541,000 | +23% y/y |
| Practice Collections · FY2025 | $3.47B | +17% y/y |
| Care Margin · FY2025 | $462M | +14% y/y |
| Platform Contribution · FY2025 | $235M | +20% y/y |
Guidance
FY2026 Adj EBITDA guidance $145M-$155M (midpoint $150M, +20% YoY); revenue $2.35B-$2.45B (midpoint $2.4B, +13% YoY)
FY2026 guidance implies continued strong growth with ~20% Adj EBITDA growth and ~80% FCF conversion
Risks flagged
Medicare Advantage market challenges; company focused on positive margin contribution in value-based risk arrangements
“Continuing to perform in value-based risk arrangements for positive margin contribution in challenging Medicare Advantage (MA) market” · word for word
8 Dec 20258-K · 8.01Disclosed a material event under other events (litigation, recall, contract loss, or major announcement)open
Risks flagged
Integration risk; no financial terms disclosed
“Acquisition closed; financial impact not disclosed; integration may affect near-term results”
6 Nov 202510-QPRVA reported strong Q3 2025 results with revenue up 32.5% YoY, Adjusted EBITDA up 61.6% YoY, and significant margin expansion driven by provider growth and value-based care.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $580M | +33% y/y |
| Adjusted EBITDA · Q3-2025 | $38M | +62% y/y |
| Implemented Providers · Q3-2025 | 5,250 | +13% y/y |
| Attributed Lives · Q3-2025 | 1,406,000 | +13% y/y |
| Practice Collections · Q3-2025 | $940M | +27% y/y |
| Care Margin · Q3-2025 | $125M | +24% y/y |
| Platform Contribution · Q3-2025 | $71M | +40% y/y |
Risks flagged
Medicare Advantage regulatory and utilization headwinds
“Given recent regulatory and utilization headwinds in Medicare Advantage, during the first quarter of 2024, the Company renegotiated certain capitation agreements for more favorable contract structures.” · word for word
Provider expense growth outpacing revenue
“Provider expenses increased 35.3% YoY vs revenue growth of 32.5% YoY for Q3 2025.”
6 Nov 20258-K · 2.02Total revenue $580M (+32% y/y); Net income $7M (+94% y/y); Adjusted EBITDA $38M (+62% y/y); Guidance: Practice Collections $3.45-3.5B, GAAP Revenue $2.05-2.1B, Care Margin $455-460M, Platform Contribution $230-235M, Adjusted EBITDA $118-121earningsopen
Figures in the filing · each found in the filing text
| Total revenue · Q3-2025 | $580M | +33% y/y |
| Net income · Q3-2025 | $7M | +94% y/y |
| Adjusted EBITDA · Q3-2025 | $38M | +62% y/y |
| Implemented Providers · Q3-2025 | 5,250 | +13% y/y |
| Value-Based Care Attributed Lives · Q3-2025 | 1,406,000 | +13% y/y |
| Practice Collections · Q3-2025 | $940M | +27% y/y |
| Care Margin · Q3-2025 | $125M | +24% y/y |
| Platform Contribution · Q3-2025 | $71M | +40% y/y |
| Gross profit · Q3-2025 | $123M | +23% y/y |
| Operating income · Q3-2025 | $14M | +148% y/y |
Guidance
Practice Collections $3.45-3.5B, GAAP Revenue $2.05-2.1B, Care Margin $455-460M, Platform Contribution $230-235M, Adjusted EBITDA $118-121M
FY2025 guidance raised above high end for all key metrics; strong Q3 performance.
Risks flagged
Acquisition integration risk; $100M cash outlay for ACO business.
“Privia Health will pay $100 million in cash at closing from its balance sheet” · word for word
28 Oct 20258-K · 8.01Disclosed a material event under other events (litigation, recall, contract loss, or major announcement)open
Risks flagged
Loss of board member and Compliance Committee Chair; potential governance impact but no immediate financial risk.
“Patricia Maryland, a member of the Board of Directors and Chair of its Compliance Committee, passed away.” · word for word
Privia Health Group, Inc. — questions
- What did Privia Health Group, Inc. file recently?
- 15 SEC filings in the last 12 months. Latest: SC 13D on 2026-09-08 — Activist investor Puma Growth Holdings (Rubicon Founders / Adam Boehler) disclosed a 5.07% passive stake in Privia Health Group, Inc.
Every figure on this page comes from Privia Health Group, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.